Evidence map›Paper›PMID 42292846›Full record

ArticleFrontiers in pharmacology2026

Pharmacology of nivegacetor (RG6289), a potent and selective gamma secretase modulator in clinical development for the treatment of Alzheimer's disease.

Lothar Lindemann, Julie Lambotte, Judith Rothe, Jürg Messer, Catherine Diener, Solen Pichereau, Carina Cantrill, Thomas Mueggler, Michael Honer, Jennifer Beck and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Lothar LindemannRoche Pharma Research & Early Development, Neuroscience and Rare Diseases Translational Area, Discovery Neuroscience, F. Hoffmann-La Roche AG, Roche Innovation Center Basel, Basel, Switzerland.
Julie LambotteRoche Pharma Research & Early Development, Neuroscience and Rare Diseases Translational Area, Discovery Neuroscience, F. Hoffmann-La Roche AG, Roche Innovation Center Basel, Basel, Switzerland.
Judith RotheRoche Pharma Research & Early Development, Neuroscience and Rare Diseases Translational Area, Discovery Neuroscience, F. Hoffmann-La Roche AG, Roche Innovation Center Basel, Basel, Switzerland.
Jürg MesserRoche Pharma Research & Early Development, Neuroscience and Rare Diseases Translational Area, Discovery Neuroscience, F. Hoffmann-La Roche AG, Roche Innovation Center Basel, Basel, Switzerland.
Catherine DienerRoche Pharma Research & Early Development, Neuroscience and Rare Diseases Translational Area, Discovery Neuroscience, F. Hoffmann-La Roche AG, Roche Innovation Center Basel, Basel, Switzerland.
Solen PichereauRoche Pharma Research & Early Development, Pharmaceutical Sciences, F. Hoffmann-La Roche AG, Roche Innovation Center Basel, Basel, Switzerland.
Carina CantrillRoche Pharma Research & Early Development, Pharmaceutical Sciences, F. Hoffmann-La Roche AG, Roche Innovation Center Basel, Basel, Switzerland.
Thomas MuegglerRoche Pharma Research & Early Development, Neuroscience and Rare Diseases Translational Area, Biomarkers, F. Hoffmann-La Roche AG, Roche Innovation Center Basel, Basel, Switzerland.
Michael HonerRoche Pharma Research & Early Development, Neuroscience and Rare Diseases Translational Area, Biomarkers, F. Hoffmann-La Roche AG, Roche Innovation Center Basel, Basel, Switzerland.
Jennifer BeckRoche Pharma Research & Early Development, Neuroscience and Rare Diseases Translational Area, Biomarkers, F. Hoffmann-La Roche AG, Roche Innovation Center Basel, Basel, Switzerland.
Thomas SteinbrecherRoche Pharma Research & Early Development, Therapeutic Modalities, Small Molecules Research, Computer Aided Drug Design, F. Hoffmann-La Roche AG, Roche Innovation Center Basel, Basel, Switzerland.
Rosanna TortelliRoche Pharma Research & Early Development, Neuroscience and Rare Diseases Translational Area, Early Clinical Development, F. Hoffmann-La Roche AG, Roche Innovation Center Basel, Basel, Switzerland.
Irene GerlachRoche Pharma Research & Early Development, Neuroscience and Rare Diseases Translational Area, Early Clinical Development, F. Hoffmann-La Roche AG, Roche Innovation Center Basel, Basel, Switzerland.
Hasane RatniRoche Pharma Research & Early Development, Therapeutic Modalities, Small Molecules Research, Medicinal Chemistry, F. Hoffmann-La Roche AG, Roche Innovation Center Basel, Basel, Switzerland.
Rosa Maria Rodriguez SarmientoRoche Pharma Research & Early Development, Therapeutic Modalities, Small Molecules Research, Medicinal Chemistry, F. Hoffmann-La Roche AG, Roche Innovation Center Basel, Basel, Switzerland.
Karlheinz BaumannRoche Pharma Research & Early Development, Neuroscience and Rare Diseases Translational Area, Discovery Neuroscience, F. Hoffmann-La Roche AG, Roche Innovation Center Basel, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Alzheimer's Disease (AD) is a prevalent neurodegenerative disorder which involves a complex pathobiology driven by amyloid-beta (Aβ) and tau pathologies, among other factors. Aβ peptides are generated Methods: The novel GSM nivegacetor was evaluated Results: Nivegacetor lowered the production of Aβ42 and Aβ40 and concomitantly increased levels of Aβ37 and Aβ38 Conclusion: Nivegacetor is a potent, orally bioavailable GSM with favorable properties and is currently under investigation as a clinical candidate in a Phase 2A clinical trial in individuals with prodromal and early sporadic AD, and in a Phase 2 clinical trial in individuals carrying the PSEN1 E280A ADAD mutation.

Indexed as

Alzheimer’s diseaseamyloid betadisease-modifying therapygamma secrease modulatorgamma secretaseGSMnivegacetorRG6289

Identifiers

PMID42292846
PMCPMC13254515

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.